Table 2 General study parameters

Woodhams [64]

2010

Prospective/single center

69

70

CA-T⁽⁴⁺⁴⁾

12.9

Tozaki [40]

2010

Prospective/single center

46 (27–61)

7

7

II

FEC 75⁽¹⁾ or FEC 75⁽⁴⁾ or FEC 100⁽⁴⁾ or FEC 75⁽²⁾ or weekly Pac⁽⁴⁾

14.3

Fangberget [65]

2011

Prospective/single center

50.7 (37–72)

Pre: 31

4 cy: 27

32

FEC⁽⁴⁺²⁾, FEC⁽⁴⁾-T(+trastuzumab if HER2+)

36.6^b

TN: 4

ER+: 21

HER2 enriched: 5

ER/Pr−/Her2+: 1

Shin [26]

2012

Retrospective/single center

41

CA⁽⁴⁾, C-T⁽⁴⁺⁴⁾, TA, FEC

36.6

Fujimoto [66]

2014

Retrospective/single center

50.9 ± 10.0 (29–70)

56

II and III

Different regimes^c

14.3^d

HER2+: 17

Hormone+: 40

Hahn [67]

2014

Retrospective/single center

43.3 (24–59)

1.5 T: 28

3.0 T: 50

78

II and III

Different combinations according to receptor status

24.4

ER+: 40/78

HER2+: 23/78

Bufi [17]

2015

Retrospective/single center

47 ± 10.1

225

II, III and IV

Combination of TAC (not specified)

17.3^e

Luminal: 143

TN: 37

HER2+/enriched:: 17

Hybrid: 28

Li [44]

2015

Prospective/single center

Median 46 (28–67)

Start: 42

1 cy: 36

II and III

Different combinations

33.3

TN: 12

Hormone+: 19

HER enriched: 11

Liu [16]

2015

Retrospective/single center

53.2 (28–68)

176

II and III

4 cycles Doxo + cyclophos (once/3 wks)-4 cycles docetaxel (once/2 wks)

Luminal A: 13.3

Luminal B: 11.9

TN: 34.3

HER2-enriched: 20.7

Luminal A: 67

Luminal B: 45

TN: 35

HER2-enriched: 29

Che [19]

2016

Not specified

50.9 ± 11.0

Pre: 36

Pre and 2 cy: 28

II and III

TA^(4–8) or TCAR

19.4

Luminal A: 4

Luminal B: 26

Basal like: 4

HER2-enriched: 2

Bedair [20]

2017

Prospective/single center

Median 53 (32–75)

Pre: 36

2 cy: 22

36

HER2−: Docetaxel⁽³⁾-FEC⁽³⁾

2pt: Taxol-FEC

HER2+: FEC⁽³⁾-Taxol Docetaxel + trastuzumab

38.8

ER+: 24/36

HER2: 13/36

Minarikova [59]

2017

Prospective/single center

52 ± 10 (29–74)

42

42

CA-T⁽⁴⁺⁴⁾, T-CA⁽⁴⁺⁴⁾, TA ^{(6 or 8)}

16.7

HER2+: 5

TN: 12

ER+ & PR+: 14

Santamaria [27]

2017

Retrospective/single center

54 (27–84)

111

TA⁽⁶⁾ (+trastuzumab in HER2+)

18.9

TN: 20

HER2+: 51

ER+/HER2−: 40

Gallivanone [21]

2017

Retrospective/single center

48 ± 12 (28–72)

Baseline: 38

Surgery: 31

Luminal A: 24%

Luminal B: 21%

HER2-enriched: 13%

TN/basal: 42%^f

Yuan [22]

2018

Prospective/single center

47.3 ± 11.0 (pCR)

43.3 ± 10.0 (non-pCR)^g

Pre till incl. 6 cy: 142

8 cy: 118

II and III

CA-T⁽⁴⁺⁴⁾ or T-CA⁽⁴⁺⁴⁾

TA^{(4,6 8)}

Extra to NAC: some cases trastuzumab in HER 2+

28.2

Luminal A: 25

Luminal B: 44

Basal like: 40

HER2-enriched: 33

Partridge [23]

2018

Prospective/multi center

48 ± 10

Pre: 242

Pre & 3 cy: 227

Pre & 12 cy: 210

Pre & post: 186

Pac ± exp agent⁽¹²⁾-A⁽⁴⁾

33

TN: 77

HER2-enriched: 24

Hormone positive: 141

Kim [53]

2018

Retrospective/not specified

45 (25–67)

46

A/cyclophos

A/T

A/cyclophos + T

A/T + trastuzumab

30.4^h (pCR: 10.9)

Ramirez-Galván [25]

2018

Prospective/single center

48.5 ± 7.8

14

16

Cyclophos + epirubicin⁽⁴⁾-Pac⁽¹²⁾

Or Clyclosphos + doxorubicin⁽⁴⁾-Pac⁽¹²⁾

HER2+: trastuzumab

Drug toxicity: replace by Carboplatin

25

Hormone+: 7

TN: 5

HER2-enriched: 4

Zhang [24]

2018

Retrospective/single center

52 ± 12.6 (26–73)

61

II and III

Pac + cisplatin

HER2: also trastuzumab

39.3

Luminal & HER2+: 30

Luminal & HER2−: 31

Pereira [18]

2019

Prospective/single center

45 (27–65)

62

62

All AC-T based:

In HER2: + trastuzumab

Or AC-T + carboplatin

Or AC-T +  (pertuzumab + Trastuzumab and docetaxel)

38.7

TN: 22

HER2-enriched: 10

Luminal B-Ki-67: 23

Luminal B-HER2: 7